Rademikibart Biosimilar – Anti-IL-4RA mAb – Research Grade from ProteoGenix; catalogue PX-TA1965; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Rademikibart Biosimilar is a novel therapeutic antibody that targets the Interleukin-4 receptor alpha (IL-4RA) and is designed for research purposes. This biosimilar is a monoclonal antibody (mAb) that mimics the structure and function of the original antibody, making it an effective tool for studying the role of IL-4RA in various biological processes.
Rademikibart Biosimilar is a recombinant antibody that is produced in a laboratory using advanced biotechnology techniques. It is composed of two identical heavy chains and two identical light chains, held together by disulfide bonds. The heavy chains contain a constant region and a variable region, while the light chains only have a variable region. The variable regions are responsible for binding to the IL-4RA target, while the constant regions provide stability and effector functions.
Rademikibart Biosimilar specifically targets the IL-4RA, which is a cell surface receptor that is involved in the immune response. IL-4RA is expressed on a variety of immune cells, including T cells, B cells, and macrophages. When IL-4RA is activated by its ligand, interleukin-4 (IL-4), it triggers a signaling cascade that leads to the activation of these immune cells.
By binding to IL-4RA, Rademikibart Biosimilar blocks the interaction between IL-4 and its receptor, thereby inhibiting the downstream signaling and activation of immune cells. This activity makes it a valuable tool for studying the role of IL-4RA in various immune processes, such as allergic responses and autoimmune diseases.
Rademikibart Biosimilar is primarily used in research settings to study the function of IL-4RA. It can be used in in vitro experiments to investigate the effects of IL-4RA signaling on different cell types. Additionally, it can be used in animal studies to assess the role of IL-4RA in disease models.
Furthermore, Rademikibart Biosimilar has potential therapeutic applications. IL-4RA is known to play a crucial role in allergic diseases, such as asthma and atopic dermatitis. By blocking IL-4RA, Rademikibart Biosimilar may have the potential to treat these conditions. Clinical trials are currently underway to evaluate the safety and efficacy of Rademikibart Biosimilar as a therapeutic antibody.
In summary, Rademikibart Biosimilar is a recombinant monoclonal antibody that targets the IL-4RA and is used for research purposes. Its unique structure and activity make it a valuable tool for studying the role of IL-4RA in immune processes. Additionally, it has potential therapeutic applications in treating allergic diseases. With ongoing research and clinical trials, Rademikibart Biosimilar has the potential to contribute to the advancement of scientific knowledge and the development of new treatments for immune-related disorders.
ProteoGenix catalogue number PX-TA1965. For research use only.
Target: Rademikibart Biosimilar – Anti-IL-4RA mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: 0.01M PBS, pH 7.4; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Rademikibart Biosimilar – Anti-IL-4RA mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
